$MYL $RHHBY $RVNC $AGN:
Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan’s …:
https://t.co/oAvELAPRiW
Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day $MYL https://t.co/U66VtDYcCT https://t.co/UdmxoRE93e
Big Call Activity https://t.co/p5v8uQbKJD $MYL $JPM $WMB $XOM $STNG $XRX $AXL $GRA $ADSK $YNDX $AAL $CI $FANG $CHK $CMG $SNAP $UAL $MS
@HalftimeReport To @terranovajoe $MA and @jonnajarian $MYL What are the catalysts for these going forward? Thanks for your time.
Mylan $MYL Rating Reiterated by Royal Bank of Canada https://t.co/L2b56PUREi #stocks
Tomorrow’s watch part 2 $V $BABA $NVDA $AMD $MU $TWTR $MSFT $INTC $QQQ $SAGE $MYL $XOM $WWE $LRCX $AA $CCL https://t.co/LT0ojNNxIW
Price Moves vs Expected Moves $TEVA $MYL $ABBV $BIIB $CELG $EXAS $GILD $PFE $AET $VRX $JNJ $MRK https://t.co/T6y5z4l70A
MACD(12, 26, 9) Bull Crossover Stock: $APC, $FTI, $IRWD, $MYL, $OAS, $SPPI, $UMUS, $WPZ https://t.co/AtNGsqXbqs
Mylan $MYL Getting Somewhat Positive Press Coverage, Analysis Finds https://t.co/iHiYxQPRPS
1/2
#FastMoneyEspresso
FINAL CALLS:
Pete Najarian —> buy $STX
Dr J —> buy $MYL
Josh Brown —> buy $NVDA https://t.co/0evtROJcZq
RT @BlackBoxTen: Tomorrow’s watch part 2 $V $BABA $NVDA $AMD $MU $TWTR $MSFT $INTC $QQQ $SAGE $MYL $XOM $WWE $LRCX $AA $CCL https://t.co/LT…
@tgtxdough $myl has to deal with patent infringement lawsuits from $amgn on its biosimilar nuelasta. courts havent… https://t.co/JQxgtLBg5n
MS $MYL Two key potential FDA approvals by mid-2018—generic Advair&Neulasta—could contribute $1.33 in EPS (29% of '… https://t.co/QHhlzl9Whm
ARGONAUT INITIATES RESEARCH COVERAGE ON MYANMAR METALS https://t.co/37KqHswo24 - Before the Argonaut research repor… https://t.co/J4bDileyVY
Mylan $MYL Getting Somewhat Positive Press Coverage, Analysis Finds https://t.co/WRqzqzFdip
RT @BlackBoxTen: Tomorrow’s watch part 2 $V $BABA $NVDA $AMD $MU $TWTR $MSFT $INTC $QQQ $SAGE $MYL $XOM $WWE $LRCX $AA $CCL https://t.co/LT…
RT @tgtxdough: MS $MYL Two key potential FDA approvals by mid-2018—generic Advair&Neulasta—could contribute $1.33 in EPS (29% of '17a EPS o…
$MYL Max Pain=40.50. Maturity=04/13/2018. #maxpain #options https://t.co/H72ktf7iML https://t.co/cLRfJ6j5Mw
@ArgonautLimited initiates coverage on Myanmar Metals Limited $MYL
https://t.co/t7XGaqFEUP
Some of the best exp… https://t.co/qXwpV7cOZs
We have previously posted a few buy examples, which have produced profits. Not past results, but notifications of a… https://t.co/G7rHIniW5o
RT @MatthewCorica: https://t.co/A5toYYWL8n #vanadium #lithium #cobalt #gold $AGK $AMP $ANZ $ASX $BHP $CBA $MYL $AVZ $TAR $KTA $WBC htt…
https://t.co/A5toYYWL8n #vanadium #lithium #cobalt #gold $AGK $AMP $ANZ $ASX $BHP $CBA $MYL $AVZ $TAR $KTA $WBC https://t.co/kD5oqnAr9U
$MYL on watch - @ArgonautLimited research report with 25c target https://t.co/GDqpwMeWVk #ASX https://t.co/K3AUqpmIHM
Taruga Gold Ltd $TAR. We are expecting further upside in the share price. Now is the time to buy back. We have been… https://t.co/dNurwPBSRD
Mylan $MYL Given a $50.00 Price Target by Morgan Stanley Analysts https://t.co/SYQ8i3RrmP
RT @owermohle: Exclusive: Women fill 28% of global drugmakers' key C-suite spots — but in China, they make up 38%, six times Europe's count…
$AMPH $INSY $MYL $PFE $OPNT https://t.co/AccA00criT
$AMPH $INSY $MYL $PFE $OPNT https://t.co/qkZFDIqLxo
@traderstewie That’s similar to what $MYL is about to do https://t.co/dkcoUqKdY3
RT @BioStocks: $MYL Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira
https://t.co/RBPYdIdtSY $ABBV
$MYL partners with Fujifilm Kyowa Kirin Biologics to commercialize #biosimilar of $ABBV #Humira… https://t.co/OUprW4uDSe
$MYL Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira
https://t.co/RBPYdIdtSY $ABBV
$CNET $VHC $CUR $SPY $IBB $USO $KONE $NTNX $AAPL $MSFT $INTC $MYL Day Trading Swing Trading Stocks Watch 4/11 https://t.co/cjT5JI3F7b
During Q4/FY17 earnings, $MYL projected '18 EPS to be $5.20-$5.60 (18% increase over '17) due on the strength of ge… https://t.co/nSU5E9y6Rb
Mylan secures exclusive rights to Humira biosimilar in Europe https://t.co/URMO77oM9R #premarket $MYL $ABBV
Mylan secures exclusive rights to Humira biosimilar in Europe https://t.co/0tESPhr602 #premarket $MYL $ABBV
Leading up to the $MYL Investor Day, what should you listen out for? Most important is guidance on the potential 20… https://t.co/nK9kIcrgZg
RT @BioStocks: $MYL Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira
https://t.co/RBPYdIdtSY $ABBV
$MYL $ABBV Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira
https://t.co/uRn5EGqdbx
$MYL 18.1m ago: Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimum… https://t.co/Vcw5Iv5tnb
$MYL:
Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize …:
https://t.co/xnv9upDoQA
$MYL Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab)
From our Stock News Alerts App
RT @odibro: $MYL Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab), acquires exclusive licen…
Mylan $MYL Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab) https://t.co/Trsf1cNR5u
@odibro Some call buying in $MYL yesterday
RT @odibro: $MYL Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab), acquires exclusive licen…
$MYL Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab), acquires exc… https://t.co/b2cmxOmX2K
$MYL:
Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize …:
https://t.co/T0sqFSlASB
RT @DonnaYoungDC: $MYL partners with Fujifilm Kyowa Kirin Biologics to commercialize #biosimilar of $ABBV #Humira https://t.co/8hy25mvOmj #…
RT @DonnaYoungDC: $MYL partners with Fujifilm Kyowa Kirin Biologics to commercialize #biosimilar of $ABBV #Humira https://t.co/8hy25mvOmj #…
$MYL $NFLX $ORCL $QCOM $SBUX $SOHU Trade long and short positions from the #NASDAQ, up to 1400% since 2011.… https://t.co/9zUiGUjUpC
RT @OpenOutcrier: $MYL (-0.5% pre) Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® - PRN
https:/…
RT @PghBizTimes: .@MylanNews acquires marketing rights to multiple sclerosis drug. https://t.co/KFV9LCgQZd #MS $MYL
$MYL (-0.5% pre) Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® - PRN
https://t.co/kvp4iBOPuc
RT @theflynews: Morgan Stanley is "optimistic" two Mylan drugs will get FDA approval by mid-year: https://t.co/Yz7dBFl53l $MYL
.@MylanNews acquires marketing rights to multiple sclerosis drug. https://t.co/KFV9LCgQZd #MS $MYL
In FY2017 earnings, $MYL reported a >$500M decline in EpiPen profits. Will the generic and biosim launches this yea… https://t.co/FCy3EC19IG